drugset / Trial / NCT06592586
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The main objective of the study is to evaluate the persistence of the immunoglobulin G (IgG) antibody responses, specific to Alpha-like protein CN (AlpCN), Ribosomal Protein N (RibN), Alpha-like protein 1N (Alp1N), and Alpha-like protein 2 and 3 (Alp2-3N), after a primary vaccination with GBS-NN/NN2 in all participants.
Timeline
- Start
- 2025-03-07
- Primary completion
- 2029-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GBS-NN/NN2 | Vaccine | 0.5 ml | — |